| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.7 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | -0.025 | 0.7 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.7 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.7 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.022 | 0.7 |